# Chiauranib

Source: https://onco.cc/drugs/chiauranib/  
OnCo record `chiauranib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chiauranib is an experimental small-molecule drug from Chipscreen Biosciences in phase 3 trials for ovarian cancer, aimed at VEGF / VEGFR and KIT.

## Summary

Chiauranib (CS2164) is a small-molecule drug developed by Chipscreen Biosciences. Its targets are VEGF / VEGFR, KIT, PDGFRA, CSF1R and Folate receptor alpha (the sponsor names VEGFR1, VEGFR2, VEGFR3, PDGFRa, c-Kit, Aurora B, CSF-1R). The sponsor states: A novel orally active multi-target inhibitor that simultaneously inhibits angiogenesis-related kinases (VEGFR1/2/3, PDGFRa, c-Kit), the mitosis-related kinase Aurora B, and the chronic-inflammation-related kinase CSF-1R at single-digit nanomolar potency. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04921527 (Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer), in ovarian cancer. The largest, NCT04921527, plans to enrol 454 participants with primary completion was scheduled for 2024-12-31 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: CS2164
- Modality: small molecule
- Mechanism: A novel orally active multi-target inhibitor that simultaneously inhibits angiogenesis-related kinases (VEGFR1/2/3, PDGFRa, c-Kit), the mitosis-related kinase Aurora B, and the chronic-inflammation-related kinase CSF-1R at single-digit nanomolar potency.

## Sources

- ClinicalTrials.gov: trials of Chiauranib: https://clinicaltrials.gov/search?intr=CS2164

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [CSF1R](https://onco.cc/targets/csf1r/), [Folate receptor alpha](https://onco.cc/targets/folr1/), [KIT](https://onco.cc/targets/kit/), [PDGFRA](https://onco.cc/targets/pdgfra/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Chipscreen Biosciences](https://onco.cc/companies/chipscreen/)
- trials: [Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer](https://onco.cc/trials/nct04921527/)

---
JSON: https://onco.cc/api/v1/entities/chiauranib.json